AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04333420
Drug: Placebo + SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase III study part: Placebo + SOC
Trial: NCT00752843
Drug: mifepristone + fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
Trial: NCT01455532
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Trial: NCT03686228
Drug: No-PB-MNC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive ASA 81 mg once daily and wound care and pain killer drug
Trial: NCT01497912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily for 8 weeks
Trial: NCT02737943
Drug: Zagazig
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
Trial: NCT03636971
Drug: hyaluronic acid with sorbitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
Trial: NCT01045577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
Trial: NCT02953847
Drug: Rimactazid 150/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
Trial: NCT03448731
Drug: Doxycycline 50Mg Tablet
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
Trial: NCT02449382
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
Trial: NCT00107965
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0025% PEP005 Topical Gel (Day 1,2 application)
Trial: NCT00107965
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% PEP005 Topical Gel (Day 1,2 application)
Trial: NCT03391609
Drug: placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
Trial: NCT03887026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT03183089
Drug: Rohto Dry-Aid®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04610567
Drug: Methotrexate-LDE phase 1
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
Trial: NCT04610567
Drug: Methotrexate-LDE phase 2
RxNorm normalized name: methotrexate 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
Trial: NCT04610567
Drug: Placebo-LDE phase 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
Trial: NCT00005944
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005944
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005944
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00892502
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
Trial: NCT05736640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02660281
Drug: Pre-Stem Cell Infusion Cyclophosphamide
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide given prior to the stem cell infusion
Trial: NCT02660281
Drug: Post-Stem Cell Infusion Cyclophosphamide
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide given after the stem cell infusion
Trial: NCT01656811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 actuations QID
Trial: NCT00836381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical Placebo once daily
Trial: NCT01794182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03131973
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03131973
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03131973
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03131973
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04448457
Drug: Sufentanil Sublingual Tablet
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mcg with lockout interval of 20 min
Trial: NCT01987739
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04523272
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT01167114
Drug: STA-9090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
Trial: NCT03371017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Trial: NCT03371017
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Trial: NCT03098654
Drug: DM/HTN medications as needed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
Trial: NCT02173678
Drug: COMBIVENT® CFC-MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01961154
Drug: Asthma medication reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
Trial: NCT01265576
Drug: VT-122 (propranolol plus etodolac)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)\[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID\]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
Trial: NCT01265576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
Trial: NCT00915876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Paricalcitol 1 mcg QD x 8 weeks
Trial: NCT02591901
Drug: Uro vaxom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevention of recurrent symptomatic lower urinary tract infections
Trial: NCT02355184
Drug: PRO 140 350mg weekly SQ injection.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCR5 Antagonist
Trial: NCT02589457
Drug: Viread® tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir Disoproxil Fumarate 1T PO
Trial: NCT03122561
Drug: Paracetamol 500 mg tablet at morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral paracetamol will be administered at 8.00 am
Trial: NCT03122561
Drug: Paracetamol 500 mg tablet at night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral paracetamol will be administered at 8.00 pm
Trial: NCT01763580
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03774524
Drug: placebo to TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 110 ml saline iv
Trial: NCT00071721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
Trial: NCT00791843
Drug: Growth hormone releasing hormone/ placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
Trial: NCT00052936
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00052936
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00052936
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01937013
Drug: Saline Nasal Mist
RxNorm normalized name: Saline Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive placebo on either study visit 2 or 3.
Trial: NCT03118492
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00068393
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
Trial: NCT00915408
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
Trial: NCT04068272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
Trial: NCT00679029
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00679029
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03018067
Drug: RDX227675
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04571437
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine metronomic combined with Letrozole
Trial: NCT01404338
Drug: Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01167738
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/mq days 1-28 every 4 weeks
Trial: NCT02469688
Drug: ASP4070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular or intradermal
Trial: NCT02469688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular or intradermal
Trial: NCT01736397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02993328
Drug: SAN021 Serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Trial: NCT03652571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01604928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04284397
Drug: Low dose ASA
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
Trial: NCT04392375
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
Trial: NCT00054938
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00054938
Drug: Vitamins: B6, B12, and folate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02161146
Drug: AGN-229666
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-229666 in the eye on Days 1 and 15.
Trial: NCT04566003
Drug: [18F]PI-2620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.
Trial: NCT04566003
Drug: [18F]MK-6240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.
Trial: NCT03709849
Drug: experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the same as group description including dosage, frequency and duration
Trial: NCT03709849
Drug: control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the same as group description including dosage, frequency and duration
Trial: NCT03092765
Drug: E6011
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT03092765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT02362672
Drug: NKTR-181 BID tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-181 tablets 100-400 mg twice daily (BID)
Trial: NCT02497040
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local injection
Trial: NCT02954692
Drug: thiazolidinediones
RxNorm normalized name: Thiazolidinediones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT02954692
Drug: alpha-glucosidase inhibitors
RxNorm normalized name: alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT01502813
Drug: Citicoline, Omega-3 Fatty Acids and Creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
Trial: NCT02954692
Drug: GLP1 Receptor Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: pen for injection~Route of administration: subcutaneous
Trial: NCT02954692
Drug: Dipeptidyl peptidase-IV (DPP-IV) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT02241083
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02241083
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01253551
Drug: Treatment sequence AB
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Trial: NCT01253551
Drug: Treatment sequence BA
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Trial: NCT02448537
Drug: PM01183
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01946022
Drug: randomization between the two GnRH analogues (agonist and antagonist)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02448537
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02593526
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diuretic
Trial: NCT01584180
Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
Trial: NCT03638999
Drug: Ketorolac Trometamol 30Mg/1mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
Trial: NCT03638999
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
Trial: NCT01542723
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
Trial: NCT02175394
Drug: Microgynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01669174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01669174
Drug: BYM338
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYM338
Trial: NCT01560325
Drug: CKD-516 inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-516: 3.3\~13mg/m2/day
Trial: NCT00757458
Drug: EDTA without re-filling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.